{'fraction_non_alphanumeric': 0.031185031185031187, 'fraction_numerical': 0.008316008316008316, 'mean_word_length': 5.602739726027397, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Vigabatrin Retinopathy in an Irish Cohort: Lack of Correlation with Dose

Summary:  Purpose: The anticonvulsant vigabatrin (VGB) causes irreversible visual‐field constriction in 19–92% of patients. It is unclear whether this correlates with dosing, and the natural history of the retinopathy remains obscure. We conducted a retrospective analysis of patients receiving long‐term VGB to examine whether toxicity is related to the daily dose, duration of therapy, or cumulative dose.